\
&
Contact us
\
&
Contact us
Published on | 11 months ago
Programmes HealthThe European Partnership for Personalised Medicine (EP PerMed) introduces two new opportunities for start-ups, researchers, and early-stage teams working on cutting-edge solutions in personalised medicine. These programmes aim to accelerate the development, validation, and market readiness of transformative innovations that enhance patient care:
Submission deadline is 13 March 2025
Find out more about both calls and how to apply on the EP PerMed website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
